ClinicalTrials.gg
CompletedNCT00522782Updated Jan 23, 2009

Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

A Phase 4 interventional study of Nebulized Budesonide and Nitric Oxide Analyzer in Asthma, sponsored by AAADRS Clinical Research Center. Completed at 1 site in United States. Open to participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2009-01-23.

Sponsored by AAADRS Clinical Research Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
4 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
99th of 108
16 · median 124
Started
2007
with 11 others
Phase 4
33 of 110
3 open now
Registered
30th of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 99th largest by enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 33 in phase 4, and was the 30th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

Read the detailed description

Comparisons will be made before and after 2 week therapy of nebulized budesonide in children not on prior anti-inflammatory medications.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthma diagnosis previously for 6 months
  • Past asthma medication without change for previous 6 months
  • Increased NO levels and ability to perform maneuver
  • ICF signed by parents

Exclusion criteria

Exclusion Criteria:

  • Systemic in past 60 days,inhaled/nebulized steroids in past 4 weeks
  • Hospitalization within 3 months
  • Upper or lower airways active infection or cigarette smoke direct exposure
  • Use of other asthma medications other than bronchodilators one month prior and during the trial
  • Noncompliance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Active comparator
    A

    Nebulized budesonide

    Drug: Nebulized Budesonide · Device: Nitric Oxide Analyzer

Interventions

  • DrugBudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pulmicort Respules 0.5mg/2cc

    Also known as: Pulmicort Respules 0.5mg/2ml nebulized

  • DeviceNitric Oxide Analyzer

    Niox NO analyzer

    Also known as: Niox NO analyzer

06

What researchers measure

Primary outcomes

  1. Exhaled breath nitric oxide pre- to post treatment

    Time frame: two weeks

Secondary outcomes

  1. Spirometry with peak flow measurements and daily diary scores

    Time frame: two weeks

07

Study locations

1 site
  • AAADRS Clinical Research Center
    Coral Gables, Florida 33134, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2007
First posted
Aug 30, 2007
Start
Aug 2007
Primary completionActual
Dec 2008
CompletionActual
Jan 2009
Last update
Jan 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00522782
Lead sponsor
AAADRS Clinical Research Center
Collaborators
AstraZeneca
First posted
Aug 30, 2007
Start date
Aug 2007
Primary completion
Dec 2008
Completion
Jan 2009
Last update
Jan 23, 2009

Study contacts

Miguel J Lanz, MD
principal investigator · Principal Investigator

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion